{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:48:39Z","timestamp":1767149319226,"version":"build-2238731810"},"reference-count":73,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","revespcardiol.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.rec.2016.07.008","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T03:10:06Z","timestamp":1475118606000},"page":"1088-1097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border"],"prefix":"10.1016","volume":"69","author":[{"given":"Bel\u00e9n","family":"Dalama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2016.07.008_bib0370","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.recesp.2013.09.031","article-title":"Prevalencia de obesidad, diabetes mellitus y otros factores de riesgo cardiovascular en Andaluc\u00eda. Comparaci\u00f3n con datos de prevalencia nacionales. Estudio Di@bet.es","volume":"67","author":"Vald\u00e9s","year":"2014","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2016.07.008_bib0375","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.recesp.2013.12.005","article-title":"Comentarios a la gu\u00eda de pr\u00e1ctica cl\u00ednica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraci\u00f3n con la European Society for the Study of Diabetes","volume":"67","year":"2014","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2016.07.008_bib0380","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1210\/jc.2002-020904","article-title":"Impairment of myocardial protection in type 2 diabetic patients","volume":"88","author":"Lee","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0385","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.diabet.2014.03.004","article-title":"Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal","volume":"40","author":"Scheen","year":"2014","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0390","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev."},{"key":"10.1016\/j.rec.2016.07.008_bib0395","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes."},{"key":"10.1016\/j.rec.2016.07.008_bib0400","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.metabol.2014.06.018","article-title":"The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors","volume":"63","author":"Wilding","year":"2014","journal-title":"Metabolism."},{"key":"10.1016\/j.rec.2016.07.008_bib0405","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.rec.2016.07.008_bib0410","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest."},{"key":"10.1016\/j.rec.2016.07.008_bib0415","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","volume":"17","author":"Del Prato","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0420","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0425","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0430","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"37","author":"Jabbour","year":"2014","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0435","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0440","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0445","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.rec.2016.07.008_bib0450","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.rec.2016.07.008_bib0455","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.12327","article-title":"Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin","volume":"16","author":"Nauck","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0460","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0465","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.rec.2016.07.008_bib0470","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"H\u00e4ring","year":"2014","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0475","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0480","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0485","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0490","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0495","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.rec.2016.07.008_bib0500","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0505","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia."},{"key":"10.1016\/j.rec.2016.07.008_bib0510","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.rec.2016.07.008_bib0515","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0520","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial","volume":"41","author":"Bode","year":"1995","journal-title":"Hosp Pract."},{"key":"10.1016\/j.rec.2016.07.008_bib0525","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0530","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest."},{"key":"10.1016\/j.rec.2016.07.008_bib0535","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.rec.2016.07.008_bib0540","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","article-title":"Canagliflozin: a review of its use in patients with type 2 diabetes mellitus","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs."},{"key":"10.1016\/j.rec.2016.07.008_bib0545","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000364909","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy","volume":"40","author":"Yamout","year":"2014","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.rec.2016.07.008_bib0550","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.rec.2016.07.008_bib0555","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rec.2016.07.008_bib0560","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jch.12425","article-title":"Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus","volume":"16","author":"Weir","year":"2014","journal-title":"J Clin Hypertens."},{"key":"10.1016\/j.rec.2016.07.008_bib0565","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0570","doi-asserted-by":"crossref","first-page":"f5680","DOI":"10.1136\/bmj.f5680","article-title":"Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials","volume":"347","author":"Ninomiya","year":"2013","journal-title":"BMJ."},{"key":"10.1016\/j.rec.2016.07.008_bib0575","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11906-014-0479-z","article-title":"Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening","volume":"16","author":"Zimlichman","year":"2014","journal-title":"Curr Hypertens Rep."},{"key":"10.1016\/j.rec.2016.07.008_bib0580","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0585","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.recesp.2014.09.005","article-title":"Obesidad y episodios vasculares en la diabetes mellitus tipo 2","volume":"68","author":"Mill\u00e1n Longo","year":"2015","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2016.07.008_bib0590","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.159.10.1104","article-title":"Clustering of metabolic factors and coronary heart disease","volume":"159","author":"Wilson","year":"1999","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.rec.2016.07.008_bib0595","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0600","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.rec.2016.07.008_bib0605","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1479164115616901","article-title":"Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus","volume":"13","author":"Neeland","year":"2016","journal-title":"Diab Vasc Dis Res."},{"key":"10.1016\/j.rec.2016.07.008_bib0610","unstructured":"ClinicalTrials.gov. Effects of dapagliflozin on epicardial fat in subjects with type 2 diabetes [accessed 2016 Apr 24]. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02235298"},{"key":"10.1016\/j.rec.2016.07.008_bib0615","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"\u0160krti\u0107","year":"2015","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.rec.2016.07.008_bib0620","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PloS One."},{"key":"10.1016\/j.rec.2016.07.008_bib0625","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0630","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0635","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0640","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.12439","article-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","volume":"17","author":"Davies","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0645","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.rec.2016.07.008_bib0650","first-page":"1","article-title":"SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment","volume":"29","author":"Scheen","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.rec.2016.07.008_bib0655","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications."},{"key":"10.1016\/j.rec.2016.07.008_bib0660","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications."},{"key":"10.1016\/j.rec.2016.07.008_bib0665","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0670","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0675","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2016.07.008_bib0680","unstructured":"ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events [accessed 2016 Apr 24]. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01730534"},{"key":"10.1016\/j.rec.2016.07.008_bib0685","unstructured":"ClinicalTrials.gov. CANVAS-canagliflozin cardiovascular assessment study [accessed 2016 Apr 24]. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01032629"},{"key":"10.1016\/j.rec.2016.07.008_bib0690","unstructured":"ClinicalTrials.gov. Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy [accessed 2016 Apr 24]. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02065791"},{"key":"10.1016\/j.rec.2016.07.008_bib0695","unstructured":"ClinicalTrials.gov. A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus [accessed 2016 Apr 24]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01989754"},{"key":"10.1016\/j.rec.2016.07.008_bib0700","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.rec.2016.07.008_bib0705","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S2213-8587(15)00426-X","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Ceriello","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.rec.2016.07.008_bib0710","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2016.07.008_bib0715","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rec.2016.07.008_bib0720","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dom.12261","article-title":"Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes","volume":"16","author":"Dziuba","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rec.2016.07.008_bib0725","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","article-title":"Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis","volume":"15","author":"Sonesson","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rec.2016.07.008_bib0730","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J."}],"updated-by":[{"DOI":"10.1016\/j.rec.2016.11.034","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000}}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585716302249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585716302249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T22:54:30Z","timestamp":1536360870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585716302249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1885585716302249"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2016.07.008","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2016.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.recesp.2016.07.029","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2016.07.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}